Binding and entering: COVID finds a new home

Michelle N. Vu¹, Vineet D. Menachery¹,²

¹ Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, United States of America, ² Institute for Human Infections and Immunity, University of Texas Medical Branch, Galveston, Texas, United States of America

*vimenach@utmb.edu

Abstract

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) emerged as a virus with a pathogenicity closer to Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) and Middle East Respiratory Syndrome Coronavirus (MERS-CoV) and a transmissibility similar to common cold coronaviruses (CoVs). In this review, we briefly discuss the features of the receptor-binding domain (RBD) and protease cleavage of the SARS-CoV-2 spike protein that enable SARS-CoV-2 to be a pandemic virus.

Introduction

A novel coronavirus (CoV), subsequently named Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), emerged in December 2019 and has caused approximately 177 million cases and approximately 3.8 million deaths worldwide (global case fatality rate (CFR) of 2.2% varying in individual countries) [1]. SARS-CoV-2 is not the first CoV to have caused a pandemic, as both Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) and Middle East Respiratory Syndrome Coronavirus (MERS-CoV) have done so previously in 2002 and 2012, respectively [2]. While the CFRs of SARS-CoV and MERS-CoV are greater than SARS-CoV-2 (11% and 34%, respectively), the earlier endemics did not reach the same scale (8,400 and approximately 2,500 cases, respectively). In contrast, human coronaviruses (hCoV-229E, hCoV-NL63, hCoV-OC43, and hCoV-HKU1) cause limited, common cold symptoms, yet have been endemic globally for decades [3]. Upon examination, there appears to be an inverse relationship between virus transmissibility and pathogenicity—the less pathogenic hCoVs have robust transmission, the highly pathogenic SARS-CoV and MERS-CoV have limited transmission, and the current SARS-CoV-2 appears to have established a rare balance between the two.

A similar trend between transmissibility and pathogenicity can be seen with influenza viruses. Like hCoVs, seasonal influenza viruses are common globally, characterized by high transmissibility, low pathogenicity with approximately 20% of the population infected, and a CFR less than 1% annually [4]. Analogous to SARS-CoV and MERS-CoV, high pathogenicity influenza strains such as H5N1 and H7N9 influenza viruses have high CFR (53% and 39%, respectively), but low transmission with approximately 1,550 and approximately 850 cases since their introduction [5,6]. The 1918 H1N1 influenza virus is comparable to SARS-CoV-2
as it achieved a balance between transmissibility and pathogenicity, with 1/3 of the world’s population infected and approximately 50 million deaths (CFR ≈ 2.5%) [7]. More recently, the H1N1 subtype caused another pandemic in 2009 with relatively robust transmissibility, although with lower pathogenicity (CFR < 0.02%) [8].

The idea of a trade-off between virulence and transmission of pathogens has long been proposed with few empirical evidence to attest to it [9,10]. However, such a relationship is clear when studying CoVs and influenza viruses (Fig 1). Both groups of viruses have strains capable of great harm (SARS-CoV, MERS-CoV, H5N1, and H7N9) yet are limited in transmission. In contrast, strains that cause mild disease (hCoVs and seasonal influenza) have been endemic globally. Then, there are viruses (SARS-CoV-2 and 1918 H1N1) that have established a key balance, capable of achieving devastating pathogenicity, but minimal loss in transmissibility. While only a few viruses have attained this balance, it is imperative to understand how these viruses emerged in order to head off the next pandemic. In this review, we focus on the start of infection, examining the impact of receptor binding and protease activation on virus tropism, transmissibility, and pathogenicity.
Location, location, location

The location in which the virus replicates along the respiratory tract guides how the virus is able to transmit and its pathogenicity. Traditionally, viruses that bind in the upper airways exhibit lower pathogenicity compensated with high transmissibility; the inverse is true for those that bind lower in the airways. For example, CoVs associated with the common cold (hCoV-229E, hCoV-NL63, hCoV-OC43, and hCoV-HKU1) replicate primarily in the upper respiratory tract including the nasal and oropharyngeal areas [11]. Testing for these less virulent hCoVs typically finds positives from upper airways samples and rarely finds lower airway infection. In turn, upper airway replication may correspond with greater transmissibility. In contrast, both SARS-CoV and MERS-CoV rarely induced positive tests from upper airway samples [12,13]. Instead, during the SARS-CoV outbreak and the later MERS-CoV emergence, samples from deep in the respiratory tract (bronchiolar lavage and sputum) were critical for diagnosis. These results suggest that the more virulent CoVs induced more replication and damage deep in the lung. The corresponding loss in lung function directly plays a role in the increased lethality associated with each. It also may explain relatively low transmission outside hospital settings and super-spreaders.

For SARS-CoV-2, a balance exists with the infection of both the upper and lower airways. Early on, testing of nasopharyngeal swabs confirmed upper airway infection with SARS-CoV-2; subsequent work found positive samples in saliva and nasal swabs suggesting replication throughout the upper airways [14]. However, lung infection as evidenced by bronchoalveolar lavage (BAL), sputum, and severe disease demonstrate robust replication in the lung in a large subset of patients [14]. This even distribution in the upper and lower airways highlight and correspond to the transmissibility and pathogenicity relationship highlighted above (Fig 1) and may offer a primer for why SARS-CoV-2 and Coronavirus Disease 2019 (COVID-19) has had such a broad impact on society.

Finding the key

Location of virus replication is in part due to receptor recognition and binding. For influenza, the viruses’ interactions between hemagglutinin and sialylated glycan receptors have been well characterized [15]. Briefly, sialic acid is linked to galactose through either an α2,3 (Sα2,3) or α2,6 (Sα2,6) linkage, which are expressed in an inverse gradient along the human respiratory tract—Sα2,6 more highly expressed in the upper airways and Sα2,3 in the lower airways [15,16]. The hemagglutinin of high pathogenicity avian influenza viruses (e.g., H7N9 and H5N1) preferentially bind to Sα2,3, directing their replication to the lower airways, limiting their transmission, but inducing more severe disease [16–18]. Conversely, human influenza viruses (e.g., H1N1 and H3N2) typically do not cause significant pathogenicity and have been observed to bind more to Sα2,6 in the upper airways, therefore affording them greater transmission opportunities [16,18]. Indeed, influenza viruses that are more transmissible via air preferentially replicate in the upper airways [19].

CoVs bind to their receptors through their spike protein, with different CoV spikes being similar at their core, but different enough in their globular head to utilize a variety of receptors. Most CoVs bind to membrane ectopeptidases—hCoV-229E to aminopeptidase N (APN); MERS-CoV to dipeptidyl peptidase-4 (DPP4); and hCoV-NL63, SARS-CoV, and SARS-CoV-2 to angiotensin converting enzyme 2 (ACE2) [20,21]. The receptors for hCoV-OC43 and hCoV-HKU1 are unknown, although they interact with acetylated sialic acids [22]. Interestingly, hCoV-NL63, SARS-CoV, and SARS-CoV-2 share the same receptor yet display distinct infection and virulence. A key to this discrepancy may be the receptor binding affinity of their spike protein. Compared to the SARS-CoV spike protein, hCoV-NL63 spike protein has less
affinity to human angiotensin converting enzyme 2 (hACE2), while SARS-CoV-2 spike protein has comparable or slightly greater affinity [23,24]. ACE2 expression follows a gradient along the respiratory tract, with greater expression in the upper airways and decreasing further down [25]. One hypothesis argues that the strength receptor affinity may correlate with receptor abundance in an inverse relationship. On one end of the spectrum, the lower receptor affinity of hCoVs may hamper potential lower respiratory infection where ACE2 is less abundant, resulting in replication primarily in the upper airways where the greater ACE2 expression offers more opportunities for binding. On the opposite end, SARS-CoV replication is predominantly observed in the lower airways, perhaps due to its strong receptor affinity allowing binding to fewer ACE2 when swept deeper. Interestingly, although the SARS-CoV-2 spike protein has similar receptor affinity as to the SARS-CoV, its infection is observed throughout the respiratory tract and with more replication in the upper airways [25]. Receptor affinity is therefore not solely responsible for where the virus replicates and subsequent effects on transmission and virulence. The spike protein interacts with other host proteins, specifically proteases, to establish successful entry and infection.

Cutting the lock

While a virus may be able to bind to its receptor, other factors are needed to establish replication. Upon receptor binding, both CoVs and influenza viruses undergo an uncoating and fusion process to release the viral genomes. Both the CoV spike protein and the influenza virus hemagglutinin are type I fusion proteins; following receptor binding, the proteins are cleaved by host proteases to prime fusion and entry with the host cell. Host proteases, such as trypsin, transmembrane serine protease 2 (TMPRSS2), furin and cathepsin, are ubiquitously expressed throughout the respiratory tract. However, due to variations in the cleavage sequences, not all proteases are the compatible. As such, the proteases used by a particular virus for cell entry may be key to its tropism.

Revisiting the previous comparison, hCoV-NL63, SARS-CoV, and SARS-CoV-2 use different host proteases despite sharing the hACE2 receptor. While hCoV-NL63 spike protein cleavage has not been studied in depth, TMPRSS2 is involved in its infection as well as in SARS-CoV and SARS-CoV-2 infection [26,27]. SARS-CoV is also capable of utilizing cathepsin while hCoV-NL63 cannot, which may explain differences in tropism [28]. Interestingly, SARS-CoV-2 spike protein has a polybasic furin cleavage site, PRRA, directly upstream of the S1/S2 cleavage site not found in other group 2B CoVs; however, furin cleavage sites are found in MERS-CoV, hCoV-OC43, and hCoV-HKU1 [24,29]. This PRRA site has been found to be necessary for efficient spike cleavage, cell entry, cell-to-cell fusion, and overall viral replication and pathogenesis of SARS-CoV-2 with its deletion attenuating replication and disease [30]. The insertion of a furin cleavage site at the S1/S2 cleavage site may contribute to the wider infection range of SARS-CoV-2 compared to SARS-CoV by expanding the pool of proteases priming entry. Similarly, influenza viruses with a multibasic cleavage sites, mainly those in the H5 and H7 subtypes, have increased virus pathogenicity compared to the H1, H2, H3, and H9 subtypes with monobasic sites [31].

Making itself at home

Receptor affinity and protease usage are crucial in the determining tropism (Fig 2). Any change affecting those factors would alter how well a virus transmits and its pathogenicity. Importantly, SARS-CoV-2 is making itself more at home in the host as mutations impacting both receptor binding and proteolytic cleavage have been observed in SARS-CoV-2 variants.
While research focus has centered on changes in the receptor-binding domain (RBD), variant mutations outside the RBD have been shown to be important. For example, the D614G variant quickly overtook the original SARS-CoV-2 strain [33–36]; positioned in the carboxyl-terminal domain of the spike protein but outside the RBD, D614G influences receptor interaction through the orientation of the spike in the up conformation [34]. Both pseudotyped virus and engineered infectious SARS-CoV-2 harboring D614G studies have shown that the D614G mutation increases virus infectivity, which, in turn, would lead to increased transmission [34–37]. The D614G mutation coupled with other RBD changes show that variant mutations impact receptor binding and affinity.

The impact of variant mutations is not limited to receptor binding and affinity. Two variants of concerns, alpha (B.1.1.7) and delta (B.1.617), have mutations within the furin cleavage site (P681H and P681R) found in the spike protein of SARS-CoV-2. Both SARS-CoV-2 variants have been observed to have increased transmission based on human cases [38,39]. In addition, our groups has demonstrated that B.1.1.7 has a replication and transmission advantage in human airway cells and the hamster models of infection, respectively [40]. Importantly, P681H and P681R in the furin cleavage site of the variant spike proteins may contribute to these differences. Initial findings with the delta variant show increased processing of the spike protein as compared to the original wild-type (WT) SARS-CoV-2 [41]. Converse to studies that removed the furin cleavage site [30], the presence of P681R mutations shifts processing more clearly to the S1/S2 cleavage product. This may contribute to changes in transmission and pathogenicity. The results also suggest an importance for proteolytic activity in SARS-CoV-2 pathogenesis and transmission.
Conclusions

The emergence and continued circulation of SARS-CoV-2 highlight the ongoing threat posed by emerging respiratory viruses. The location, receptor binding, and proteolytic activation of CoVs dictates critical elements of transmissibility and pathogenicity. In this regard, SARS-CoV-2 has achieved an unfortunate balance, allowing for a worldwide outbreak with parallels to the 1918 H1N1 outbreak from a century earlier. Importantly, understanding how replication location, receptor interactions, and protease activation drive virus emergence and spread is paramount in disrupting and possibly preventing future emergence events.

References

1. Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis. 2020; 20(5):533–4. https://doi.org/10.1016/S1473-3099(20)30120-1 PMID: 32087114
2. Gralinski LE, Menachery VD. Return of the Coronavirus: 2019-nCoV. Viruses. 2020; 12(2). https://doi.org/10.3390/v12020135 PMID: 32915141.
3. Su S, Wong G, Shi W, Liu J, Lai ACK, Zhou J, et al. Epidemiology, Genetic Recombination, and Pathogenesis of Coronaviruses. Trends Microbiol. 2016; 24(6):490–502. https://doi.org/10.1016/j.tim.2016.03.003 PMID: 27012512.
4. Iuliano AD, Roguski KM, Chang HH, Muscatello DJ, Paley S, et al. Estimates of global seasonal influenza-associated respiratory mortality: a modelling study. Lancet. 2018; 391(10127):1286–300. https://doi.org/10.1016/S0140-6736(17)33293-2 PMID: 2928255.
5. World Health Organization. Cumulative number of confirmed human cases of avian influenza A(H5N1) reported to WHO. 2020 [cited 2020 May 20]. https://www.who.int/influenza/human_animal_interface/2020_MAY_tableH5N1.pdf?ua=1.
6. Food and Agriculture Organization of the United Nations. H7N9 situation update. [cited 2020 20 May]. http://www.fao.org/ag/againfo/programmes/en/empres/H7N9/situation_update.html.
7. Taubenberger JK, Morens DM. 1918 Influenza: the Mother of All Pandemics. Emerg Infect Dis. 2006; 12(1):15–22. https://doi.org/10.3201/eid1201.050979 PMID: 16494711.
8. Van Kerkhove MD, Hirve S, Koukounari A, Mounts AW. Estimating age-specific cumulative incidence for the 2009 influenza pandemic: a meta-analysis of A(H1N1)pdm09 serological studies from 19 countries. Influenza Other Respir Viruses. 2013; 7(5):872–86. https://doi.org/10.1111/irv.12074 PMID: 23331969.
9. Acevedo MA, Dillemuth FP, Flick AJ, Faldyn MJ, Elderd BD. Virulence-driven trade-offs in disease transmission: A meta-analysis. Evolution. 2019; 73(4):836–47. Epub 2019 Feb 9. https://doi.org/10.1111/evo.13692 PMID: 30734920.
10. Hector TE, Booksmythe I. Digest: Little evidence exists for a virulence-transmission trade-off. Evolution. 2019; 73(4):858–9. Epub 2019 Mar 23. https://doi.org/10.1111/evo.13724 PMID: 30900249.
11. Lepiller Q, Barth H, Lefebvre F, Herbrecht R, Lutz P, Kessler R, et al. High incidence but low burden of coronaviruses and preferential associations between respiratory viruses. J Clin Microbiol. 2013; 51(9):3039–46. Epub 2013 Jul 12. https://doi.org/10.1128/JCM.01078-13 PMID: 23850984.
12. Cheng PK, Wong DA, Tong LK, Ip S-M, Lo AC, Lau C-S, et al. Viral shedding patterns of coronavirus in patients with probable severe acute respiratory syndrome. Lancet. 2004; 363(9422):1699–700. https://doi.org/10.1016/S0140-6736(04)16255-7 PMID: 15158632.
13. Corman VM, Albarrak AM, Omrani AS, Albarrak MM, Farah ME, Almasri M, et al. Viral Shedding and Antibody Response in 37 Patients With Middle East Respiratory Syndrome Coronavirus Infection. Clin Infect Dis. 2016; 62(4):477–83. Epub 2015 Nov 12. https://doi.org/10.1093/cid/civ851 PMID: 26565003.
14. Liu R, Han H, Liu F, Lv Z, Wu K, Liu Y, et al. Positive rate of RT-PCR detection of SARS-CoV-2 infection in 4880 cases from one hospital in Wuhan, China, from Jan to Feb 2020. Clin Chim Acta. 2020; 506:172–5. Epub 2020 Mar 7. https://doi.org/10.1016/j.cca.2020.03.009 PMID: 32196607.
15. De Graaf M, Fouchier RAM. Role of receptor binding specificity in influenza A virus transmission and pathogenesis. EMBO J. 2014; 33(9):823–41. https://doi.org/10.1002/embj.201303442 PMID: 24668228.
16. Shinya K, Ebina M, Yamada S, Ono M, Kasai N, Kawaoka Y. Influenza virus receptors in the human airway. Nature. 2006; 440(7083):435–6. https://doi.org/10.1038/440435a PMID: 16654799.
17. Xiong X, Martin SR, Haire LF, Wharton SA, Daniels RS, Bennett MS, et al. Receptor binding by an H7N9 influenza virus from humans. Nature. 2013; 499(7459):496–9. https://doi.org/10.1038/nature12372 PMID: 23738794.
18. Zeng H, Goldsmith CS, Kumar A, Belser JA, Sun X, Pappas C, et al. Tropism and infectivity of a Seasonal A(H1N1) and a Highly Pathogenic Avian (H5N1) Influenza Virus in Primary Differentiated Ferret Nasal Epithelial Cell Cultures. J Virol. 2019; 93(10):e00080–19. https://doi.org/10.1128/JVI.00080-19 PMID: 30814288

19. Richard M, van den Brand JMA, Bestebroer TM, Lexmond P, de Meulder D, Fouchier RAM, et al. Influenza A viruses are transmitted via the air from the nasal respiratory epithelium of ferrets. Nat Commun. 2020; 11(1):766. https://doi.org/10.1038/s41467-020-14626-0 PMID: 32034144

20. Fehr AR, Perlman S. Coronaviruses: An Overview of Their Replication and Pathogenesis. New York: Springer; 2015. p. 1–23.

21. Shang J, Ye G, Shi K, Wan Y, Luo C, Alhara H, et al. Structural basis of receptor recognition by SARS-CoV-2. Nature. 2020; 581(7807):221–4. https://doi.org/10.1038/s41586-020-2179-y PMID: 32225175

22. Hulswit RJG, Lang Y, Bakkers MJG, Li W, Li Z, Schouten A, et al. Human coronaviruses OC43 and HKU1 bind to 9-O-acetylated sialic acids via a conserved receptor-binding site in spike protein domain A. Proc Natl Acad Sci U S A. 2019; 116(7):2681–90. https://doi.org/10.1073/pnas.1806671116 PMID: 30679277

23. Mathewson AC, Bishop A, Yao Y, Kemp F, Ren J, Chen H, et al. Interaction of severe acute respiratory syndrome-coronavirus and NL63 coronavirus spike proteins with angiotensin converting enzyme-2. J Gen Virol. 2008; 89(11):2741–5. https://doi.org/10.1099/vir.0.003962-0 PMID: 18931070

24. Walls AC, Park Y-J, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell. 2020; 181(2):81–92.e6. https://doi.org/10.1016/j.cell.2020.02.058 PMID: 32155444

25. Hou YJ, Okuda K, Edwards CE, Martinez DR, Asakura T, Dinnon KH, et al. SARS-CoV-2 Reverse Genetics Reveals a Variable Infection Gradient in the Respiratory Tract. Cell. 2020; 182(2):429–46. e14. https://doi.org/10.1016/j.cell.2020.05.042 PMID: 32142651

26. Kawase M, Shirato K, van der Hoek L, Taguchi F, Matsuya M. Simultaneous treatment of human bronchial epithelial cells with serine and cysteine protease inhibitors prevents severe acute respiratory syndrome coronavirus entry. J Virol. 2012; 86(12):6537–45. Epub 2012 Apr 13. https://doi.org/10.1128/JVI.00094-12 PMID: 22496216.

27. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger T, Erichsen S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020; 181(2):271–80.e8. https://doi.org/10.1016/j.cell.2020.02.052 PMID: 32142651

28. Huang IC, Bosch BJ, Li F, Li W, Lee KH, Ghiran S, et al. SARS coronaviruses, but not human coronaviruses NL63, utilizes cathepsin L to infect ACE2-expressing cells. J Biol Chem. 2006; 281(6):3198–203. Epub 2006 Mar 15. https://doi.org/10.1074/jbc.M508381200 PMID: 16339146.

29. Hoffmann M, Kleine-Weber H, Pöhlmann S. A Multibasic Cleavage Site in the Spike Protein of SARS-CoV-2 Is Essential for Infection of Human Lung Cells. Mol Cell. 2020; 82(6):812–27.e19. Epub 2020 Jul 23. https://doi.org/10.1016/j.molcel.2020.06.043 PMID: 32697968.

30. Johnson BA, Xie X, Bailey AL, Kalveram B, Lokugamage KG, Munato A, et al. Loss of furin cleavage site attenuates SARS-CoV-2 pathogenesis. Nature. 2021. Epub 2021 Jan 26. https://doi.org/10.1038/s41586-021-03237-4 PMID: 33494095.

31. Bölttcher-Friebertshäuser E, Garten W, Matrosovich M, Klenk HD. The hemagglutinin: a determinant of pathogenicity. Curr Top Microbiol Immunol. 2014; 385:3–34. Epub 2014 Jul 18. https://doi.org/10.1007/82_2014_384 PMID: 25031010.

32. Plante JA, Mitchell BM, Plante KS, Debinkin K, Weaver SC, Menachery VD. The variant gambit: COVID-19’s next move. Cell Host Microbe. 2021; 29(4):508–15. Epub 2021 Apr 1. https://doi.org/10.1016/j.chom.2021.02.020 PMID: 33789086.

33. Korber B, Fischer WM, Gnanakaran S, Yoon H, Theiler J, Abfalterer W, et al. Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus. Cell. 2020; 182(4):812–27.e19. Epub 2020 Jul 23. https://doi.org/10.1016/j.cell.2020.06.043 PMID: 32697968.

34. Yurkovetskiy L, Wang X, Pascal KE, Tomkins-Tinch C, Nyallie TP, Wang Y, et al. Structural and Functional Analysis of the D614G SARS-CoV-2 Spike Protein Variant. Cell. 2020; 183(3):739–51.e8. Epub 2020 Sep 30. https://doi.org/10.1016/j.cell.2020.09.032 PMID: 32991842.

35. Plante JA, Liu Y, Liu J, Xia H, Johnson BA, Lokugamage KG, et al. Spike mutation D614G alters SARS-CoV-2 fitness. Nature. 2020. https://doi.org/10.1038/s41586-020-2895-3 PMID: 33106671

36. Hou YJ, Chiba S, Halfmann P, Ehre C, Kuroda M, Dinnon KH, et al. SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivo. Science. 2020; 370(6523):1464–8. https://doi.org/10.1126/science.abe8499 PMID: 33184236

37. Zhang L, Jackson CB, Mou H, Oja H, Peng H, Quinlan BD, et al. SARS-CoV-2 spike-protein D614G mutation increases virion spike density and infectivity. Nat Commun. 2020; 11(1):6013. https://doi.org/10.1038/s41467-020-19086-4 PMID: 33243994
38. Confirmed Cases of COVID-19 Variants Identified in UK. 2021 [cited 2021 Apr 28]. www.gov.uk.

39. Goncalves Cabecinhas AR, Roloff T, Stange M, Bertelli C, Huber M, Ramette A, et al. SARS-CoV-2 N501Y Introductions and Transmissions in Switzerland from Beginning of October 2020 to February 2021-Implementation of Swiss-Wide Diagnostic Screening and Whole Genome Sequencing. Microorganisms. 2021; 9(4). Epub 2021 Apr 4. https://doi.org/10.3390/microorganisms9040677 PMID: 33806013.

40. Liu Y, Liu J, Plante KS, Plante JA, Xie X, Zhang X, et al. The N501Y spike substitution enhances SARS-CoV-2 transmission. bioRxiv. 2021. Epub 2021 Mar 25. https://doi.org/10.1101/2021.03.08.434499 PMID: 33758836.

41. Peacock TP, Sheppard CM, Brown JC, Goonawardane N, Zhou J, Whiteley M, et al. The SARS-CoV-2 variants associated with infections in India, B.1.617, show enhanced spike cleavage by furin. bioRxiv. 2021. https://doi.org/10.1101/2021.05.28.446163